Rasna Therapeutics, Inc. is a clinical stage biotechnology company, which engages in the development of therapeutics for the treatment of leukemia and lymphoma diseases. It develops small molecule drug candidates that focus on treating acute myeloid leukemia. The company was founded in 2013 and is headquartered in New York, NY.
Company profile
Ticker
RASP
Exchange
Website
CEO
Kunwar Shailubhai
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
Active With Me Inc., Rasna Therapeutics Inc.
SEC CIK
Corporate docs
Subsidiaries
Rasna Research, Inc. ...
RASP stock data
Latest filings (excl ownership)
8-K
Changes in Registrant's Certifying Accountant
10 Apr 24
10-Q
2024 Q1
Quarterly report
16 Feb 24
NT 10-Q
Notice of late quarterly filing
14 Feb 24
10-K
2023 FY
Annual report
5 Jan 24
NT 10-K
Notice of late annual filing
29 Dec 23
8-K
Amendments to Articles of Incorporation or Bylaws
25 Oct 23
10-Q
2023 Q3
Quarterly report
14 Aug 23
10-Q
2023 Q2
Quarterly report
15 May 23
10-Q
2023 Q1
Quarterly report
2 Mar 23
10-K
2022 FY
Annual report
9 Feb 23
Latest ownership filings
No filings
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Sep 23 | Sep 22 | Sep 21 | Sep 20 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 74.99 k | 74.99 k | 74.99 k | 74.99 k | 74.99 k | 74.99 k |
Cash burn (monthly) | (no burn) | (no burn) | 16.28 k | 353.20 k | (no burn) | 709.67 |
Cash used (since last report) | n/a | n/a | 112.03 k | 2.43 mm | n/a | 4.88 k |
Cash remaining | n/a | n/a | -37.04 k | -2.36 mm | n/a | 70.10 k |
Runway (months of cash) | n/a | n/a | -2.3 | -6.7 | n/a | 98.8 |